Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations.

Cortiula, Francesco; De Ruysscher, Dirk; Steens, Michelle; Wijsman, Robin; van der Wekken, Anthonie; Alberti, Martina; Hendriks, Lizza E L

Cortiula, Francesco; De Ruysscher, Dirk; Steens, Michelle; Wijsman, Robin; van der Wekken, Anthonie; Alberti, Martina; Hendriks, Lizza E L.

Afiliación

Cortiula F; Department of Oncology, University Hospital of Udine, Udine, Italy; Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, School for Oncology and Reproduction (GROW), Maastricht, the Netherlands. Electronic address: francesco.cortiula@asufc.sanita.fvg.it.
De Ruysscher D; Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, School for Oncology and Reproduction (GROW), Maastricht, the Netherlands.
Steens M; Department of Pulmonology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.
Wijsman R; Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
van der Wekken A; Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Alberti M; Department of Oncology, University Hospital of Udine, Udine, Italy.
Hendriks LEL; Department of Pulmonology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: https://twitter.com/@HendriksLizza.

Eur J Cancer ; 184: 172-178, 2023 05.

Article en En | MEDLINE | ID: mdl-36931075

Asunto(s)

Antineoplásicos Inmunológicos; Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Humanos; Carcinoma de Pulmón de Células no Pequeñas/terapia; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Neoplasias Pulmonares/terapia; Neoplasias Pulmonares/tratamiento farmacológico; Estudios Retrospectivos; Proteínas Proto-Oncogénicas p21(ras)/genética; Antineoplásicos Inmunológicos/uso terapéutico; Estadificación de Neoplasias; Quimioradioterapia/métodos; Adyuvantes Inmunológicos/uso terapéutico; Genómica; Receptores ErbB/genética

Palabras clave

Adjuvant immunotherapy; Driver genomic alterations; KRAS mutation; Progression-free survival; Stage III NSCLC; Uncommon driver genomic alterations; Unresectable NSCLC

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Antineoplásicos Inmunológicos / Neoplasias Pulmonares Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google